Frequently Asked Questions

1. What is the collaboration between Stanford University and Deerfield Management Company?
Stanford University is collaborating with Deerfield, an investment firm dedicated to advancing healthcare, to accelerate the translation of research emerging from Stanford University. The collaboration, Porter Alliance for Innovative Medicines, is a private company wholly owned by affiliates of Deerfield Management. Its objective is to fund projects that discover novel therapeutics that have the potential to cure life-altering diseases. This collaboration will rely on the robust and diverse drug pipeline established by Stanford’s Innovative Medicines Accelerator (IMA) and will leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Deerfield has committed up to $130 million and additional scientific and operational support.
2. Who is eligible to apply?
Principal Investigators whose principal employer is Stanford University or who have a faculty appointment at Stanford University and are therefore subject to Stanford University’s institutional policies are eligible to apply.
3. How can I apply?
Interested faculty should reach out to Paul Humphries at for more information on proposal submission.
4. Does Porter Alliance have a therapeutic area of interest?
No. Porter Alliance welcomes applications from all therapeutic areas and modalities.